Literature DB >> 27768231

Combined Post- and Precapillary Pulmonary Hypertension in Patients With Heart Failure.

Michael E Rezaee1,2, Elizabeth L Nichols2, Mandeep Sidhu3, Jeremiah R Brown2,4,5.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is a well-recognized complication of left ventricular heart failure (HF). HYPOTHESIS: Differences exist in demographic, clinical, hemodynamic, and survival characteristics of patients with left ventricular HF who have combined postcapillary and precapillary PH (CpcPH), isolated postcapillary PH, or no PH.
METHODS: A secondary data analysis was conducted using a large prospective database of patients undergoing right heart catheterization from 1994 to 2012. One-year mortality postcatheterization was assessed between PH groups using Kaplan-Meier and log-rank techniques, as well as a multivariate Cox proportional hazards model adjusted for age, sex, diabetes, chronic kidney disease, atrial fibrillation, and chronic obstructive pulmonary disease. Mortality rates were calculated for each group as deaths per 100 person-years.
RESULTS: Of the 724 patients identified, 29.4% (n = 213) had no evidence of PH, 63.1% (n = 457) had isolated postcapillary PH, and 7.5% (n = 54) had CpcPH. Compared with no PH, there was an increased mortality rate within 1 year for CpcPH patients (crude hazard ratio: 5.22, 95% confidence interval: 2.06-13.22), but not for isolated postcapillary PH patients (crude hazard ratio: 2.12, 95% confidence interval: 0.99-4.57). Adjusted analyses revealed similar results. Mortality rates per 100 person-years were 3.9, 8.4, and 21.0 for no PH, isolated postcapillary PH, and CpcPH patients, respectively.
CONCLUSIONS: Heart failure patients with CpcPH are associated with increased death rate 1 year post-cardiac catheterization, compared with patients without PH. They are a high-risk PH group and should be evaluated and diagnosed earlier in the disease state.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Epidemiology; Heart failure/cardiac transplantation/cardiomyopathy/myocarditis; Pulmonary hypertension

Mesh:

Year:  2016        PMID: 27768231      PMCID: PMC6490872          DOI: 10.1002/clc.22579

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  27 in total

1.  Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Authors:  Marco Guazzi; Marco Vicenzi; Ross Arena; Maurizio D Guazzi
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

2.  Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?

Authors:  Aaron B Waxman
Journal:  Circulation       Date:  2011-07-12       Impact factor: 29.690

Review 3.  Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies.

Authors:  Francois Haddad; Kristina Kudelko; Olaf Mercier; Bojan Vrtovec; Roham T Zamanian; Vinicio de Jesus Perez
Journal:  Prog Cardiovasc Dis       Date:  2011 Sep-Oct       Impact factor: 8.194

4.  Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure.

Authors:  S Ghio; A Gavazzi; C Campana; C Inserra; C Klersy; R Sebastiani; E Arbustini; F Recusani; L Tavazzi
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

5.  Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure.

Authors:  Doron Aronson; Amnon Eitan; Robert Dragu; Andrew J Burger
Journal:  Circ Heart Fail       Date:  2011-05-23       Impact factor: 8.790

6.  Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction.

Authors:  Thenappan Thenappan; Sanjiv J Shah; Mardi Gomberg-Maitland; Brett Collander; Ajay Vallakati; Pranavkumar Shroff; Stuart Rich
Journal:  Circ Heart Fail       Date:  2011-03-16       Impact factor: 8.790

7.  Prognostic importance of pulmonary hypertension in patients with heart failure.

Authors:  Jesper Kjaergaard; Dilek Akkan; Kasper Karmark Iversen; Erik Kjoller; Lars Køber; Christian Torp-Pedersen; Christian Hassager
Journal:  Am J Cardiol       Date:  2007-03-08       Impact factor: 2.778

8.  Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk.

Authors:  Thomas P Cappola; G Michael Felker; W H Linda Kao; Joshua M Hare; Kenneth L Baughman; Edward K Kasper
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

9.  Comparing methods for identifying patients with heart failure using electronic data sources.

Authors:  Fadi Alqaisi; L Keoki Williams; Edward L Peterson; David E Lanfear
Journal:  BMC Health Serv Res       Date:  2009-12-18       Impact factor: 2.655

10.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study.

Authors:  Carolyn S P Lam; Véronique L Roger; Richard J Rodeheffer; Barry A Borlaug; Felicity T Enders; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2009-03-31       Impact factor: 24.094

View more
  5 in total

1.  How does severe functional mitral regurgitation redefined by European guidelines affect pulmonary vascular resistance and hemodynamics in heart transplant candidates?

Authors:  Zübeyde Bayram; Cem Doğan; Rezzan Deniz Acar; Süleyman Efe; Özgür Yaşar Akbal; Fatih Yılmaz; Büşra Güvendi Şengör; Ahmet Karaduman; Samet Uysal; Ali Karagöz; Çağatay Önal; Mehmet Kaan Kırali; Cihangir Kaymaz; Nihal Özdemir
Journal:  Anatol J Cardiol       Date:  2021-06       Impact factor: 1.596

2.  Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities.

Authors:  I-Hsin Tai; Tsung-Cheng Shyu; Kai-Sheng Hsieh; Ke-Wei Chen; Wan-Jane Tsai; Kuo-Yang Wang
Journal:  Front Cardiovasc Med       Date:  2022-09-07

3.  Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.

Authors:  Julio D Duarte; Mayank Kansal; Ankit A Desai; Katherine Riden; Meghan J Arwood; Alex A Yacob; Thomas D Stamos; Larisa H Cavallari; Roham T Zamanian; Sanjiv J Shah; Roberto F Machado
Journal:  Pulm Circ       Date:  2018 Apr-Jun       Impact factor: 3.017

4.  Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension.

Authors:  Bin Q Yang; Tufik R Assad; Jared M O'Leary; Meng Xu; Stephen J Halliday; Reid W D'Amico; Eric H Farber-Eger; Quinn S Wells; Anna R Hemnes; Evan L Brittain
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

5.  Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension.

Authors:  Meghan J Arwood; Nasim Vahabi; Christelle Lteif; Ravindra K Sharma; Roberto F Machado; Julio D Duarte
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.